Drug Information

Drug (ID: DG01845) and It's Reported Resistant Information

• Name: Nonesterified
• Synonyms: NEFA; JMF9RU2BLC; UNII-JMF9RU2BLC; Fatty Acids, Nonesterified; SCHEMBL15273327; Q6953452; (4aR,9aS)-N-Ethyl-4,4a,9,9a-tetrahydro-1H-fluoren-4a-amine; 4Ah-fluoren-4a-amine, N-ethyl-1,4,9,9a-tetrahydro-, (4ar-cis)-; 127140-88-9
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Nonalcoholic fatty liver disease [ICD-11: DB92]; [1]
• Target: .; NOUNIPROTAC; [2]
• Formula: 2
• IsoSMILES: CCN[C@]12CC=CC[C@H]1CC3=CC=CC=C23
• InChI: InChI=1S/C15H19N/c1-2-16-15-10-6-5-8-13(15)11-12-7-3-4-9-14(12)15/h3-7,9,13,16H,2,8,10-11H2,1H3/t13-,15+/m0/s1
• InChIKey: DRCWOKJLSQUJPZ-DZGCQCFKSA-N
• PubChem CID: 57426056

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-13: Digestive system diseases

Nonalcoholic fatty liver disease [ICD-11: DB92]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: Maternally expressed 3 (MEG3) [2]

• Molecule Alteration: Down-regulation; Expression
• Resistant Disease: Nonalcoholic fatty liver disease [ICD-11: DB92.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HepG2 cells; Liver; Homo sapiens (Human); CVCL_0027
• In Vivo Model: C57BL/6 mice model; Mus musculus
• Experiment for Molecule Alteration: Overexpression assay; Dual luciferase assay
• Experiment for Drug Resistance: MTT assay
• Mechanism Description: LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6.

Key Molecule: H19, imprinted maternally expressed transcript (H19) [1]

• Molecule Alteration: Up-regulation; Interaction
• Resistant Disease: Nonalcoholic fatty liver disease [ICD-11: DB92.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Huh-7 cells; Liver; Homo sapiens (Human); CVCL_0336
• In Vitro Model: HepG2 cells; Liver; Homo sapiens (Human); CVCL_0027
• In Vivo Model: C57BL/6 mice model; Mus musculus
• Experiment for Molecule Alteration: IHC staining assay; ELISA assay; Luciferase assay; RNA pull down assay; qRT-PCR; Western bloting analysis; Overexpression assay; Knockdown assay
• Mechanism Description: LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPAR gama axis in nonalcoholic fatty liver disease.

References

• Ref 1: Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axisAnticancer Drugs. 2020 Jun;31(5):473-482. doi: 10.1097/CAD.0000000000000888.
• Ref 2: LncRNA MEG3 contributes to adenosine-induced cytotoxicity in hepatoma HepG2 cells by downregulated ILF3 and autophagy inhibition via regulation PI3K-AKT-mTOR and beclin-1 signaling pathwayJ Cell Biochem. 2019 Oct;120(10):18172-18185. doi: 10.1002/jcb.29123. Epub 2019 May 29.